



# BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS", NO.299, THAMBU CHETTY STREET, CHENNAI – 600001, TAMIL NADU, INDIA  
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com  
CIN: L24294TN1995PLCO30698

Date: September 11, 2026

To

|                                                                                        |                                                                                                                               |
|----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|
| <b>BSE Limited,</b><br>Phiroze Jeejeebhoy Towers,<br>Dalal Street,<br>Mumbai - 400001. | <b>National Stock Exchange of India Limited,</b><br>Exchange Plaza,<br>Bandra Kurla Complex,<br>Bandra East, Mumbai – 400051. |
| Scrip Code: 532989                                                                     | Scrip Code: BAFNAPH                                                                                                           |

Dear Sir/Madam,

**Subject: Disclosure Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015 -  
Proceedings of 31<sup>st</sup> Annual General Meeting of M/s. Bafna Pharmaceuticals Limited  
Held on September 11, 2026**

We wish to inform you that the 31<sup>st</sup> Annual General Meeting (AGM) of the Company was held on **Friday, September 11, 2026, at 10:00 A.M (IST)** through **Video Conferencing (VC) / Other Audio-Visual Means (OAVM)**.

In this connection, we hereby enclose the Summary of the Proceedings of the 31<sup>st</sup> AGM of the Company, as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Summary of the Proceedings of the 31<sup>st</sup> AGM is also being uploaded on the website of the Company [www.bafnapharma.com](http://www.bafnapharma.com).

We request you take the information on record.

Thanking You.

For **BAFNA PHARMACEUTICALS LIMITED**

**Mohanachandran A**  
Company Secretary & Compliance Officer

Enclosed: As Above



# BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS", NO.299, THAMBU CHETTY STREET, CHENNAI – 600001, TAMIL NADU, INDIA  
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com  
CIN: L24294TN1995PLCO30698

## **SUMMARY OF PROCEEDINGS OF 31<sup>ST</sup> ANNUAL GENERAL MEETING OF THE COMPANY**

The Thirty First Annual General Meeting (31<sup>st</sup> AGM) of Bafna Pharmaceuticals Limited was held on Friday, September 11, 2026 through Video Conferencing (VC) / Other Audio Visual Means (OAVM) at 10.00 A.M (IST), in compliance with the circulars issued by Ministry of Corporate Affairs and the Securities and Exchange Board of India.

Mr. A. Mohanachandran, Company Secretary, welcomed the Members to the 31<sup>st</sup> AGM and briefed them on the details relating to their participation in the Meeting through Audio-Visual means. Further, the Registers as required under the Companies Act, 2013 were made available for inspection through electronic mode.

Mrs. Ravichandran Chitra, Chairperson of the Board of the Company occupied the Chair and conducted the proceedings of the Meeting. Upon ascertaining that the requisite quorum was present, the Chairperson called the meeting to order.

The Chairperson welcomed the Members of the Company and introduced the Directors, Key Managerial Personnel, Statutory Auditors, Scrutinizer and Secretarial Auditor present in the Meeting. She informed that, the Notice of Annual General Meeting along with the Annual Report for financial year 2025-2026 were sent by e-mail to all members whose e-mail IDs were registered with the Company / Depositories on August 19, 2026. The Chairperson delivered her Speech and requested Ms. S Hemalatha, Whole Time Director to provide the business overview & performance highlights of the Company for the Financial Year 2025-2026.

Ms. S Hemalatha, Whole Time Director of the Company, presented an overview of the Company's business, performance highlights for the financial year 2025-2026 and future outlook for the Company. She expressed her gratitude to the Shareholders, Board of Directors, Employees and all stakeholders for their continued trust and support.

The Chairperson then proceeded with the agenda of the Annual General Meeting. With the permission of the members, the Notice convening the 31<sup>st</sup> AGM was taken as read.

The Company Secretary then read out the Qualifications made in the Independent Auditors' Report and the Secretarial Audit Report, along with the explanations, replies provided by the Board of Directors of the Company.



# BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS", NO.299, THAMBU CHETTY STREET, CHENNAI – 600001, TAMIL NADU, INDIA  
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com  
CIN: L24294TN1995PLCO30698

The Company Secretary also informed the Members that in compliance with Section 108 of the Companies Act, 2013, that the Company has engaged CDSL to provide remote e-voting facility, e-voting at the AGM to cast vote electronically, on all resolutions set-out in the Notice convening the 31<sup>st</sup> AGM and enable members to participate in AGM electronically. The remote e-voting facility was made available to the members for a period of three days from Tuesday, September 08, 2026 (9:00 AM) to Thursday, September 10, 2026 (05.00 PM).

He further stated that Mr. Balu Sridhar, Partner, M/s. A.K. Jain & Associates, Company Secretaries, Chennai, has been appointed as Scrutinizer for the remote e-voting and e-voting during the AGM. The Company Secretary explained the procedure for question & answer session to the Members who had registered themselves as Speakers and requested them to offer their comments, suggestions or raise queries, if any.

Mr. Bafna Mahaveer Chand, Chief Executive Officer of the Company addressed the queries raised by members of the Company.

The following businesses were transacted at the 31st Annual General Meeting of the Company:

| S. No | Particulars of Agenda                                                                                                                                                                                          |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1     | Adoption of Audited Financial Statements of the Company for the financial year ended March 31, 2026, together with the Reports of the Board of Directors and Auditor's thereon. – <i>Ordinary Resolution</i> . |
| 2     | Re-appointment of Mr. Upendar Mekala Reddy (DIN: 08898174), as Director of the Company, who retires by rotation and being eligible, offers himself for re-appointment. – <i>Ordinary Resolution</i> .          |
| 3     | Ratification of Remuneration payable to Cost Auditors M/s. N. Sivashankaran & Co., Cost Accountants (ICMAI FRN. 100662), Chennai for the F.Y 2026-2027. – <i>Ordinary Resolution</i> .                         |

The Chairperson informed that members who did not exercise their vote by remote e-voting may cast their vote through the CDSL e-voting facility and would continue to be available for the next 30 minutes from the conclusion of the meeting. She further informed that the voting results would be declared within two working days of the



# BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS", NO.299, THAMBU CHETTY STREET, CHENNAI – 600001, TAMIL NADU, INDIA  
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com  
CIN: L24294TN1995PLCO30698

conclusion of the Meeting. Further, the Voting Results along with the Scrutinizer Report will be uploaded on the website of the Company and Stock Exchanges.

The Chairperson thanked all the Members, Directors and Invitees present and concluded the meeting. After the conclusion of meeting the venue e-voting was extended to the members of the Company.

The 31<sup>st</sup> Annual General Meeting commenced at 10.00 A.M and concluded at 10.35 A.M.

Thanking You.

For **BAFNA PHARMACEUTICALS LIMITED**

**Mohanachandran A**

Company Secretary & Compliance Officer

\* \* \* \* \*